These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
810 related articles for article (PubMed ID: 28984814)
1. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI. Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814 [TBL] [Abstract][Full Text] [Related]
2. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis. He X; Sun L; Huo Y; Shao M; Ma C Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer. Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913 [TBL] [Abstract][Full Text] [Related]
5. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases. Shao M; Zi J; Wen G J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884 [TBL] [Abstract][Full Text] [Related]
6. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295 [TBL] [Abstract][Full Text] [Related]
7. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009 [TBL] [Abstract][Full Text] [Related]
8. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients. An YS; Lee DH; Yoon JK; Lee SJ; Kim TH; Kang DK; Kim KS; Jung YS; Yim H Nuklearmedizin; 2014; 53(3):89-94. PubMed ID: 24220324 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
11. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study. van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091 [TBL] [Abstract][Full Text] [Related]
12. Predictive Value of Song BI; Kim HW; Won KS Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480 [TBL] [Abstract][Full Text] [Related]
13. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited. Zhang X; Wu F; Han P Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754 [TBL] [Abstract][Full Text] [Related]
14. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766 [TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866 [TBL] [Abstract][Full Text] [Related]
16. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
18. 18F-fluorodeoxyglucose PET/computed tomography in locoregional staging and assessment of biological and clinical aggressiveness of breast cancer subtypes. Ozkan EE; Sengul SS; Erdogan M; Gurdal O; Eroglu HE Nucl Med Commun; 2019 Oct; 40(10):1043-1050. PubMed ID: 31425343 [TBL] [Abstract][Full Text] [Related]
19. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750 [TBL] [Abstract][Full Text] [Related]
20. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]